Physician profile
Tedi E Payne
NPI 1083055800
$980.39
in general payments reported to CMS, 2019-2025
16 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2023: $405 · 2024: $212 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.85 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $175.06 | 2022-2024 | Breztri, Farxiga |
| Amgen INC. | $91.45 | 2022-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $81.17 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $75.75 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.56 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $56.64 | 2022-2023 | Verquvo, Belsomra |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Novo Nordisk INC | $33.01 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $22.70 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.29 | 2022 | |
| Astellas Pharma US INC | $15.83 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $15.36 | 2024 | |
| Mylan Specialty L.P. | $14.74 | 2024 | Yupelri |
| Organon LLC | $14.41 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $13.31 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedi Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.